Ginkgo Bioworks Holdings Inc. [DNA] Is Currently -5.12 below its 200 Period Moving Avg: What Does This Mean?

Ginkgo Bioworks Holdings Inc. [NYSE: DNA] slipped around -0.15 points on Friday, while shares priced at $2.78 at the close of the session, down -5.12%. The company report on August 24, 2022 that Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture                                         .

Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company’s chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC).

Ginkgo Bioworks Holdings Inc. stock is now -66.55% down from its year-to-date (YTD) trading value. DNA Stock saw the intraday high of $2.94 and lowest of $2.74 per share. The company’s 52-week high price is 15.86, which means current price is +33.01% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 26.38M shares, DNA reached a trading volume of 21657327 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Ginkgo Bioworks Holdings Inc. [DNA]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $7.98 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for Ginkgo Bioworks Holdings Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 18, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on March 02, 2022, representing the official price target for Ginkgo Bioworks Holdings Inc. stock. Previously, the target price had yet another raise to $7, while Goldman analysts kept a Neutral rating on DNA stock.

The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc. is set at 0.34, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 8.14. The Price to Book ratio for the last quarter was 2.93, with the Price to Cash per share for the same quarter was set at 0.87.

How has DNA stock performed recently?

Ginkgo Bioworks Holdings Inc. [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.46. With this latest performance, DNA shares dropped by -2.11% in over the last four-week period, additionally sinking by -36.96% over the last 6 months – not to mention a drop of -72.12% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 43.79, with the RSI for the last a single of trading hit 40.48, and the three-weeks RSI is set at 45.81 for Ginkgo Bioworks Holdings Inc. [DNA]. The present Moving Average for the last 50 days of trading for this stock 2.94, while it was recorded at 2.79 for the last single week of trading, and 5.06 for the last 200 days.

Ginkgo Bioworks Holdings Inc. [DNA]: Deeper insight into the fundamentals

Ginkgo Bioworks Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.80 and a Current Ratio set at 11.80.

Insider trade positions for Ginkgo Bioworks Holdings Inc. [DNA]

There are presently around $2,183 million, or 84.10% of DNA stock, in the hands of institutional investors. The top three institutional holders of DNA stocks are: BAILLIE GIFFORD & CO with ownership of 205,327,786, which is approximately 22.399% of the company’s market cap and around 0.50% of the total institutional ownership; ARK INVESTMENT MANAGEMENT LLC, holding 87,358,057 shares of the stock with an approximate value of $242.85 million in DNA stocks shares; and VANGUARD GROUP INC, currently with $241.12 million in DNA stock with ownership of nearly 195.687% of the company’s market capitalization.

Positions in Ginkgo Bioworks Holdings Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 176 institutional holders increased their position in Ginkgo Bioworks Holdings Inc. [NYSE:DNA] by around 233,357,848 shares. Additionally, 71 investors decreased positions by around 113,528,395 shares, while 40 investors held positions by with 438,313,336 shares. The mentioned changes placed institutional holdings at 785,199,579 shares, according to the latest SEC report filing. DNA stock had 100 new institutional investments in for a total of 44,043,747 shares, while 30 institutional investors sold positions of 17,881,548 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here